Study Purpose:
To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral SclerosisStudy Status:
Not recruiting
Disease:
Japanese Patients With ALS
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
MT-1186
Placebo:
No
Phase:
Phase 1
Study Chair(s)/Principal Investigator(s):
General Manager, Mitsubishi Tanabe Pharma Corporation
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Study Sponsor:
Mitsubishi Tanabe Pharma Corporation
Estimated Enrollment:
9
Estimated Study Start Date:
04 / 17 / 2019
Estimated Study Completion Date:
09 / 04 / 2019
Posting Last Modified Date:
11 / 25 / 2019
Date Study Added to neals.org:
11 / 25 / 2019
Minimum Age:
20 Years
Maximum Age:
75 Years
Inclusion Criteria:The key criteria are listed below.
- Patients aged between 20 and 75 years at the time of informed consent
- Japanese patients
- Among patients with ALS, those "Clinically definite ALS," "Clinically probable ALS" or "Clinically probable-laboratory-supported ALS" according to El Escorial Revised Airlie House criteria
- Patients who can consent to contraception
- Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study
Exclusion Criteria:
The key criteria are listed below.
- Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy
- Patients undergoing treatment for malignancy
- Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator
- Body mass index (BMI) of <18.0 or >30.0, or a body weight of <50 kg
- Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Investigational site
Tokyo
Japan